Next-Generation CTLA-4 Therapy in Squamous NSCLC

In this segment, the panel discusses next-generation CTLA-4-directed therapies being engineered with the goal of improving selectivity and reducing the systemic toxicities associated with earlier CTLA-4 inhibitors in advanced squamous non-small cell lung cancer (NSCLC). The discussion begins with the importance of multidisciplinary collaboration, particularly as newer treatment modalities such as cell therapy expand into solid tumors. Dr. Christian Rolfo then describes how pharmaceutical engineering is being used to modify the characteristics of CTLA-4-directed agents, with the intention of creating a wider therapeutic window. He explains that some newer compounds are designed to alter antibody behavior and promote internalization and degradation of CTLA-4, rather than relying solely on sustained surface binding. The panel discusses early clinical experience suggesting that these approaches may reduce toxicity, while emphasizing that immune-related adverse events can still occur. The experts note that confirmatory studies will be important to determine whether these engineered approaches can maintain antitumor activity while providing a more favorable safety profile.